India has capped trade margins on 137 anti-cancer medicines at 30%, with revised prices taking effect on November 9. The move could lower costs for patients, but the actual reduction will depend on each medicine’s existing price and the revised maximum retail price.
India’s National Pharmaceutical Pricing Authority (NPPA) has set a 30% limit on trade margins for 137 non-scheduled anti-cancer medicines. The revised prices are due to come into effect on November 9, 2026. The NPPA cancer drug price cap measure aims to limit mark-ups across the medicine supply chain and improve affordability for patients. The amount saved will differ from one medicine to another, depending on its existing maximum retail price (MRP).
On October 17, 2026, the NPPA released the notification by invoking Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013. The NPPA cancer drug price cap is intended to regulate trade margins on covered medicines, but it does not guarantee the same percentage reduction for every product.
For patients and caregivers, the key question is whether their prescribed medicines will become cheaper and how they can check the revised prices.
What Is the New NPPA Cancer Drug Price Cap?
The new policy limits trade margins on 137 non-scheduled anti-cancer medicines to 30%, according to the reported notification. Trade margin represents the difference between a medicine’s procurement cost at a particular distribution level and the amount charged when it is sold to the next buyer.
By regulating these mark-ups, the government aims to prevent excessive increases in medicine prices as products move through the supply chain. The measure covers specified anti-cancer formulations, with the exact coverage determined by the official notification.
The NPPA cancer drug price cap is part of India’s existing drug-pricing framework. Paragraph 19 of the DPCO, 2013, allows the government to act in the public interest to regulate the prices of certain drug formulations.
Will Cancer Medicines Become 70% Cheaper?
Not really. The new trade-margin limit does not mean that all anti-cancer medicines covered by the order will see their prices fall by 70%. The cap regulates trade margins rather than setting a uniform percentage reduction in the MRP of every medicine.
The final price adjustment will vary based on each cancer medicine’s current cost and the new price determined under the applicable regulations. A formulation priced above its newly applicable permitted MRP may require a reduction, while another product may experience a different change.
Once the revised rates come into force, patients should check the updated price of their specific medicine and formulation against its earlier MRP.
The policy also does not guarantee a similar reduction in the total cost of cancer treatment. Hospital charges, diagnostic tests, consultations, procedures and other medicines may continue to contribute to a patient’s overall expenses.
Which Cancer Medicines Are Covered?
The order covers 137 non-scheduled anti-cancer medicines. Reported examples include atezolizumab, bevacizumab, daratumumab, enzalutamide, erlotinib, ipilimumab and lapatinib.
Please note that the above-given names should not be treated as the complete list. Patients and caregivers should consult the official NPPA notification to confirm whether a prescribed medicine, strength and dosage form are covered.
Checking the exact formulation is important because products containing the same active ingredient may differ in strength, dosage form and other details relevant to price regulation. Patients should not assume that a medicine is covered or excluded solely because of its brand name.
What Are the Important Dates and Requirements?
The NPPA released the order on October 17, 2026, with the updated medicine prices set to come into force from November 9, 2026.
| Policy detail | Information |
| Notification date | October 17, 2026 |
| Medicines covered | 137 non-scheduled anti-cancer medicines |
| Trade-margin cap | 30% |
| Effective date | November 9, 2026 |
| Regulatory framework | DPCO, 2013 |
Manufacturers and other affected businesses should follow the notification’s provisions on revised prices, reporting and compliance. The precise pricing formula and applicable deadlines should be checked against the complete order rather than inferred from the 30% figure.
Why Does the New Policy Matter?
Cancer care often requires patients to buy medicines regularly over several months or years. If the updated rates lower the cost of medicines included in the order, the revised trade-margin rules could help ease some of the financial pressure on patients and their families.
The NPPA’s decision also has implications for pharmaceutical manufacturers, distributors, pharmacies and hospitals, which need to ensure that their pricing practices comply with the applicable regulations.
India has previously used trade-margin regulation to address anti-cancer medicine prices. According to the NPPA’s official background information, a 2019 initiative covered 42 non-scheduled anti-cancer drugs. The authority reported that the earlier measure reduced the MRPs of 526 brands and generated estimated annual savings of ₹984 crore.
These estimates refer to the previous initiative and do not represent the expected savings from the 2026 policy. The actual benefits of the latest measure will depend on the updated prices, the range of medicines included and how effectively the new pricing rules are enforced.
How Can Patients Check Revised Cancer Drug Prices?
Patients can take the following steps to understand whether the policy affects their prescriptions:
- Check the medicine details: Note the active ingredient, brand, strength and dosage form.
- Consult the official notification: Visit the NPPA website and check the complete list of covered medicines.
- Compare prices: Check the previous MRP against the applicable revised price after November 9.
- Keep purchase bills: Retain pharmacy invoices if the amount charged appears inconsistent with the permitted price.
- Report suspected overcharging: Contact the NPPA through its official website or consumer helpline at 1800-111-255, listed for working days between 10 am and 6 pm.
The NPPA cancer drug price cap regulates prices for covered medicines; it does not replace medical advice. Patients should not stop, delay or change prescribed cancer treatment because of a price update without consulting their treating doctor.
What Happens Next?
The revised prices are scheduled to take effect on November 9, 2026. Patients, healthcare providers and medicine sellers will need to check the applicable prices and follow the relevant requirements.
The NPPA cancer drug price cap may help improve affordability for some patients, but its actual effect will become clearer from the revised prices for individual formulations and compliance with the notification.
For the most accurate information, patients should refer to the official NPPA website and its notifications and orders. These sources should be used to confirm medicine coverage, applicable prices and regulatory requirements.
Also read: What happened to Darya Shipilova as suspected plague triggers quarantine measures in Russia
